Global Liquid Biopsy Market: Analysis By Biomarkers (C-Tumor Cells, C-Tumor DNA, Vesicles), Cancer Type, By Product (Instruments, Reagents), By Region, By Country (2019 Edition): Opportunities and Forecast (2017-2024)
SKU ID :Azoth-14857866 | Published Date: 31-Oct-2019 | No. of pages: 200Description
Executive Summary
According to research report, the Liquid Biopsy was valued at USD 899.55 million for the year 2018.
Over the recent years, Liquid Biopsy has been witnessing considerable growth on the back of growing focus on immunotherapy to cure cancer and shifting trend towards precision medicine along with high per capita healthcare expenditure and rapid adoption of novel diagnostic test by oncologist. Further, rising awareness for the early detection of cancer and sharp rise in its incidences have contributed to the growth rate of Liquid Biopsy Market.
Among the Circulating Biomarker, Ct- DNA is the most used biomarker for the diagnosis in pre and post cancerous stage, as it provides more comprehensive overview of the tumor genomic status. Ongoing research and clinical trials suggest that exosomes and nucleosomes, will provide more efficient diagnostic results and hence market will be growing in the forecast period.
In the forecast period, continuous research and development by private manufacturers, government organizations and designated government labs along with growing number of clinical trials in liquid biopsy is anticipated to provide momentum to the market growth. However, generation of revenue from the liquid biopsy is dependent upon the interest of third party payers, hindering the market growth.
Scope of the Report
Global Liquid Biopsy Market (Actual Period: 2017-2018,
• Liquid Biopsy Market: Size, Growth, Forecast
• Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
• Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
• Analysis By Product Type: Reagents, Instruments
Regional Liquid Biopsy Markets - North America, Europe, APAC, ROW (Actual Period: 2017-2018,
• Liquid Biopsy Market: Size, Growth, Forecast
• Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
• Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
• Analysis By Product Type: Reagents, Instruments
Country Analysis – U.S., Germany, France, Japan (Actual Period: 2017-2018,
• Liquid Biopsy Market: Size, Growth, Forecast
• Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
• Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
• Analysis By Product Type: Reagents, Instruments
Company Analysis – Roche Diagnostics, Thermo Fisher Scientific, Guardant Health, Qiagen.
Other Report Highlights
•
• Investment and Partnerships
• Product Analysis
• Market Dynamics – Drivers and Restraints.
• Market Trends
• Porter Five Forces Analysis.
• SWOT Analysis.
Customization of the Report
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
According to research report, the Liquid Biopsy was valued at USD 899.55 million for the year 2018.
Over the recent years, Liquid Biopsy has been witnessing considerable growth on the back of growing focus on immunotherapy to cure cancer and shifting trend towards precision medicine along with high per capita healthcare expenditure and rapid adoption of novel diagnostic test by oncologist. Further, rising awareness for the early detection of cancer and sharp rise in its incidences have contributed to the growth rate of Liquid Biopsy Market.
Among the Circulating Biomarker, Ct- DNA is the most used biomarker for the diagnosis in pre and post cancerous stage, as it provides more comprehensive overview of the tumor genomic status. Ongoing research and clinical trials suggest that exosomes and nucleosomes, will provide more efficient diagnostic results and hence market will be growing in the forecast period.
In the forecast period, continuous research and development by private manufacturers, government organizations and designated government labs along with growing number of clinical trials in liquid biopsy is anticipated to provide momentum to the market growth. However, generation of revenue from the liquid biopsy is dependent upon the interest of third party payers, hindering the market growth.
Scope of the Report
Global Liquid Biopsy Market (Actual Period: 2017-2018,
Forecast Period:
2019-2024)• Liquid Biopsy Market: Size, Growth, Forecast
• Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
• Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
• Analysis By Product Type: Reagents, Instruments
Regional Liquid Biopsy Markets - North America, Europe, APAC, ROW (Actual Period: 2017-2018,
Forecast Period:
2019-2024)• Liquid Biopsy Market: Size, Growth, Forecast
• Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
• Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
• Analysis By Product Type: Reagents, Instruments
Country Analysis – U.S., Germany, France, Japan (Actual Period: 2017-2018,
Forecast Period:
2019-2024)• Liquid Biopsy Market: Size, Growth, Forecast
• Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
• Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
• Analysis By Product Type: Reagents, Instruments
Company Analysis – Roche Diagnostics, Thermo Fisher Scientific, Guardant Health, Qiagen.
Other Report Highlights
•
Competitive Landscape
- Sales, Segments, Market Share, Business Strategies• Investment and Partnerships
• Product Analysis
• Market Dynamics – Drivers and Restraints.
• Market Trends
• Porter Five Forces Analysis.
• SWOT Analysis.
Customization of the Report
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
TOC
Tables & Figures
Companies
- PRICE
-
$1800$2400Buy Now